Cardiovascular disease in Africa: epidemiological profile and challenges.
Ashley K Keates, Ana O Mocumbi, Mpiko Ntsekhe...
https://pubmed.ncbi.nlm.nih.gov/28230175/Actively Recruiting
Led by Magdi Yacoub Heart Foundation · Updated on 2024-05-29
5000
Participants Needed
1
Research Sites
213 weeks
Total Duration
This research aims to understand cardiovascular disease CVD in the Ballana population in Egypt by studying its incidence, prevalence, progression, and risk factors including genetic background. The study will create a valuable foundation for cardiovascular research and assist in designing future studies and informing health policies. It focuses on defining the cardiovascular characteristics, genetic information, and other biological markers for CVD in this population over a long period. The study will randomly select 1,200 households in Ballana to participate. After enrolling, participants will have their cardiovascular profiles assessed, including clinical, laboratory, and genetic data collection. High-risk participants will be followed annually, while others will be evaluated every three years. This follow-up will continue for up to 30 years to monitor changes and cardiovascular events. Participants will be involved in regular assessments of their cardiovascular health, including risk evaluations and data collection on genetics and other health indicators. Researchers will continuously monitor cardiovascular risk over the 30-year period. The study includes consent procedures and requires participants to have a valid National ID. The long-term follow-up will provide detailed information on cardiovascular risk and progression in this community.
CONDITIONS
AHC Ballana Heart Study
Y
Yasmine Aguib, PhD
A
Ahmed Elguindy, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Magdi Yacoub Heart Foundation
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Initial assessment at enrollment
Participants undergo cardiovascular risk assessment including clinical, laboratory, and genetic data collection after providing informed consent.
1 visit (in-person)
Duration - Up to 30 years
Participants are followed up for changes in their cardiovascular profile and cardiovascular events over time.
Annual visits for high risk participants; every 3 years for others
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Ashley K Keates, Ana O Mocumbi, Mpiko Ntsekhe...
https://pubmed.ncbi.nlm.nih.gov/28230175/Magdi Yacoub Heart Foundation
Lead Sponsor